Prognostic value of post-ablation
131I
children
post-ablation scintigraphy
prognosis
thyroid cancer
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
04
11
2019
revised:
01
01
2020
accepted:
10
01
2020
pubmed:
25
1
2020
medline:
22
6
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
To evaluate the prognostic value of post-ablation whole-body scintigraphy (PAS) in children with thyroid cancer following A retrospective analysis of children with thyroid cancer who underwent remnant ablation was performed. PAS results were correlated with clinical and histopathologic characteristics of the primary tumor and compared with the follow-up data. One hundred and sixty-eight children were eligible for the analysis. The median age was 17 years, and the majority were female (81.5%). In multivariate analysis, N1b classification and PAS could provide prognostic information in children with thyroid cancer undergoing
Sections du résumé
BACKGROUND
To evaluate the prognostic value of post-ablation whole-body scintigraphy (PAS) in children with thyroid cancer following
METHODS
A retrospective analysis of children with thyroid cancer who underwent remnant ablation was performed. PAS results were correlated with clinical and histopathologic characteristics of the primary tumor and compared with the follow-up data.
RESULTS
One hundred and sixty-eight children were eligible for the analysis. The median age was 17 years, and the majority were female (81.5%). In multivariate analysis, N1b classification and
CONCLUSIONS
PAS could provide prognostic information in children with thyroid cancer undergoing
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1738-1745Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25:716-759.
Verburg FA, Mader U, Luster M, Hanscheid H, Reiners C. Determinants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2015;42:1390-1398.
Sherman SI, Tielens ET, Sostre S, Wharam MDJ, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629-634.
Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573-577.
Souza Rosario PW, Barroso AL, Rezende LL, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795-798.
Donahue KP, Shah NP, Lee SL, Oates ME. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy. Radiology. 2008;246:887-894.
Tian T, Kou Y, Huang R, Liu B. Prognosis of high-risk papillary thyroid cancer patients with pre-ablation stimulated Tg <1 Ng/mL. Endocr Pract. 2019;25:220-225.
Tian T, Huang R, Liu B. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment? Endocrine. 2019;65:149-154.
Liu L, Huang F, Liu B, Huang R. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin. J Pediatr Endocrinol Metab. 2018;31:751-756.
Kim HY, Gelfand MJ, Sharp SE. SPECT/CT imaging in children with papillary thyroid carcinoma. Pediatr Radiol. 2011;41:1008-1012.
Liu B, Chen Y, Jiang L, He Y, Huang R, Kuang A. Is postablation whole-body 131I scintigraphy still necessary in intermediate-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL? Clin Endocrinol. 2017;86:134-140.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
Sohn SY, Kim YN, Kim HI, Kim TH, Kim SW, Chung JH. Validation of dynamic risk stratification in pediatric differentiated thyroid cancer. Endocrine. 2017;58:167-175.
Sapuppo G, Tavarelli M, Belfiore A, Vigneri R, Pellegriti G. Time to separate persistent from recurrent differentiated thyroid cancer: different conditions with different outcomes. J Clin Endocrinol Metab. 2019;104:258-265.
Tracy ET, Roman SA. Current management of pediatric thyroid disease and differentiated thyroid cancer. Curr Opin Oncol. 2016;28:37-42.
Bernier MO, Withrow DR, Berrington de Gonzalez A, et al. Trends in pediatric thyroid cancer incidence in the United States, 1998-2013. Cancer. 2019;125:2497-2505.
Weissman S. Personalized medicine: a new horizon for medical therapy. Precis Clin Med. 2018;1:1-2.
Mostafa M, Vali R, Chan J, Omarkhail Y, Shammas A. Variants and pitfalls on radioiodine scans in pediatric patients with differentiated thyroid carcinoma. Pediatr Radiol. 2016;46:1579-1589.
Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B. Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following 131I treatment: a systematic review. Thyroid. 2010;20:1095-1101.
Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V. Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl Med Mol Imaging. 2011;38:651-655.
Markovina S, Grigsby PW, Schwarz JK, et al. Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid. 2014;24:1121-1126.
Mihailovic J, Nikoletic K, Srbovan D. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes. J Nucl Med. 2014;55:710-717.
Pires BP, Alves PA Jr, Bordallo MA, et al. Prognostic factors for early and long-term remission in pediatric differentiated thyroid carcinoma: the role of sex, age, clinical presentation, and the newly proposed American Thyroid Association risk stratification system. Thyroid. 2016;26:1480-1487.
Na'ara S, Mahameed K, Amit M, et al. Efficacy of posttreatment radioiodine scanning in patients with differentiated thyroid cancer. Head Neck. 2019;41:3235-3240.
Zhang XY, Song HJ, Qiu ZL, et al. Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I. Endocrine. 2018;62:149-158.